Jeffrey S. Farrow
CIK: 0001405253
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (20 total)
- Jul 27, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectStock Option (right to buy)
25K shares- - Jul 27, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectRestricted Stock Unit (RSU)
16.7K shares- - Jun 16, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct14.4K shares at avg. $60.95$877K - Jun 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct27.9K shares- - May 29, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectStock Option (right to buy)
47.3K shares- - Mar 19, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct2.2K shares at avg. $67.00$146K - Mar 18, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct2.1K shares at avg. $68.71$147K - Mar 17, 2026TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct2.1K shares at avg. $69.42$147K - Mar 15, 2026TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct13K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30.7K shares- - Mar 5, 2026TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
19.3K shares- - Jun 17, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct13.6K shares at avg. $40.42$550K - Jun 16, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct27.9K shares- - Mar 20, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct1.2K shares at avg. $50.11$59K - Mar 19, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct1.3K shares at avg. $47.40$59K - Mar 18, 2025TARS
Tarsus Pharmaceuticals, Inc.
Sale(S)Direct1.3K shares at avg. $46.29$59K - Mar 17, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)DirectRestricted Stock Units
8K shares- - Mar 15, 2025TARS
Tarsus Pharmaceuticals, Inc.
Exercise(M)Direct8K shares- - Mar 5, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
30.6K shares- - Mar 5, 2025TARS
Tarsus Pharmaceuticals, Inc.
Award(A)DirectRestricted Stock Units
20.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 27, 2026 |  ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Stock Option (right to buy) | 25,000 | - | - | Direct |
| Jul 27, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Restricted Stock Unit (RSU) | 16,700 | - | - | Direct |
| Jun 16, 2026 |  TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 14,396 | $60.95 | $877,436 | Direct |
| Jun 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 27,881 | - | $0 | Direct |
| May 29, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Stock Option (right to buy) | 47,250 | - | - | Direct |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,186 | $67.00 | $146,462 | Direct |
| Mar 18, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,133 | $68.71 | $146,558 | Direct |
| Mar 17, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 2,111 | $69.42 | $146,546 | Direct |
| Mar 15, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 13,042 | - | $0 | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,724 | - | - | Direct |
| Mar 5, 2026 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 19,306 | - | - | Direct |
| Jun 17, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 13,608 | $40.42 | $550,035 | Direct |
| Jun 16, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 27,881 | - | - | Direct |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 1,186 | $50.11 | $59,430 | Direct |
| Mar 19, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 1,254 | $47.40 | $59,440 | Direct |
| Mar 18, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Sale(S) | 1,284 | $46.29 | $59,436 | Direct |
| Mar 17, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) Restricted Stock Units | 8,019 | - | - | Direct |
| Mar 15, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Exercise(M) | 8,019 | - | - | Direct |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 30,628 | - | - | Direct |
| Mar 5, 2025 | TARS Tarsus Pharmaceuticals, Inc. | Award(A) Restricted Stock Units | 20,089 | - | - | Direct |
1-20 of 20 transactions
About Farrow Jeffrey S
Farrow Jeffrey S (SEC CIK 0001405253) files insider reports with the SEC as Director of LISATA THERAPEUTICS, INC. (LSTA), Director of ACHIEVE LIFE SCIENCES, INC. (ACHV) and Officer of Tarsus Pharmaceuticals, Inc. (TARS).
Signal8 holds 12 ownership filings by Farrow Jeffrey S (2 Form 3, 10 Form 4), filed between Mar 7, 2025 and Oct 15, 2026. Those filings report 20 transactions, from Mar 5, 2025 to Jul 27, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Farrow Jeffrey S's filings is in LIBERTY CORNER, NJ.
Recent filings by Farrow Jeffrey S
- Jul 27, 2026: Grants or awards of ACHV derivative securities (2 lines, Form 4, code A).
- Jun 16, 2026: Open-market sale of TARS shares (Form 4, code S).
- Jun 15, 2026: Option exercise of TARS shares (Form 4, code M).
- May 29, 2026: Grant or award of ACHV derivative securities (Form 4, code A).
- Mar 19, 2026: Open-market sale of TARS shares (Form 4, code S).
Other insiders filing for LISATA THERAPEUTICS, INC. (LSTA)
- LOVE TED W, Director
- Lehrer-Graiwer Joshua, President & COO
- Mazzo David J, President & CEO
- Nisco James, SVP, Fin/Treas, Chief Actg Off
- Imam Tariq, SVP, Bus Dev, General Counsel
- Buck Kristen K, EVP, R&D and CMO